Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
14/04/2026 21:32
April 14 (Reuters) - Cabaletta Bio Inc CABA.O: FIRST PATIENTS DOSED WITH CABALETTA BIO’S RESE-CEL MANUFACTURED ON CELLARES' AUTOMATED CELL SHUTTLE™ PLATFORM Source text: ID:nBw8B8Lnda Further company coverage: CABA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity